UNASSIGNED: 396 Background: The International mRCC Database Consortium (IMDC) Prognostic Model (Heng, et al. model, JCO, 2009) was defined and validated in a @entity1 cohort that was comprised of @entity1358 of all histological-subtypes. Clear-cell @entity1358 (ccRCC) accounts for ~80% of @entity1358 cases, and thus it is unknown if this model is reliable in @entity1 with non-ccRCC (nccRCC). Therefore, we sought to evaluate the reliability of the model separately in ccRCC and nccRCC. METHODS: Data on 2,215 (1,963 ccRCC/252 n-ccRCC) @entity1 treated with 1-st line VEGF-and @entity3470 targeted therapies were collected from the IMDC. nccRCC included papillary, chromophobe, and other histologies. @entity1 were assigned to favorable, intermediate, and poor prognosis groups according to the ICDM prognostic model. The discrimination ability for @entity1349 ( @entity1349 ) was evaluated by C-index. RESULTS: The median @entity1349 of the entire cohort was 20.9 months. nccRCC @entity1 were of younger age (p < 0.0001), more often presented with low Hb (p = 0.014) and elevated neutrophils (p = 0.0001), but displayed otherwise similar clinicopathological features compared to ccRCC. @entity1349 (22.3 vs. 12.8 months; p < 0.0001), and TTF (7.8 vs. 4.2 months; p < 0.0001) were worse in nccRCC compared to ccRCC. The hazard ratio for @entity204 ( @entity1349 ) and treatment failure (TTF) when adjusted for the prognostic factors was 1.41 (95%CI 1.19, 1.67, p < 0.0001) and 1.54 (95% CI 1.33, 1.79, p < 0.0001), respectively. The IMDC prognostic model reliably discriminated three risk groups to predict @entity1349 and TTF in nccRCC; the median @entity1349 and TTF of favorable, intermediate, and poor prognosis groups were 31.4, 16.1, and 5.1 months (p < 0.0001) and 9.6, 4.9, and 2.1 months (p < 0.0001), respectively. The C-indices for @entity1349 were 0.66 and 0.64 for the IDCM and MSKCC criteria, respectively. CONCLUSIONS: @entity1 with nccRCC treated with targeted therapies have a significantly worse outcome than ccRCC @entity1 . The IMDC prognostic model reliably predicts @entity1349 and TTF in nccRCC and ccRCC.

Metastatic non-clear cell @entity1358 (nccRCC) treated with targeted therapy agents: Applying the International XXXX Database Consortium (IMDC) prognostic model to predict outcomes.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity3470 :: ('21977(Tax:10090)', 'Gene') :: ['mTOR'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['RCC'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1358 :: (MESH:D002292,Disease) :: ['Metastatic Renal Cell Carcinoma']
